Last reviewed · How we verify

NCT06569810

Real-world Registry Study of Red Light Treatment on Myopia Control: a Focus on Non-responders to Conventional Treatments

Not yet recruiting Last updated 26 August 2024
What this trial tests

trial testing Repeated Low-Level Red Light (RLRL) therapy in Myopia in 2,500 participants. Not yet recruiting.

Timeline
1 September 2024
Primary endpoint
1 August 2026
1 September 2026

Quick facts

Lead sponsorThe Hong Kong Polytechnic University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment2,500
Start date1 September 2024
Primary completion1 August 2026
Estimated completion1 September 2026

Drugs / interventions tested

Conditions studied

Sponsor

The Hong Kong Polytechnic University

Who can join

Adults 8 to 16, any sex, with Myopia or Repeated Low-level Red Light. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This real-world observational registry study aims to assess the effectiveness of Repeated Low-Level Red Light (RLRL) therapy in controlling myopia progression among children aged 8 to 16 who have not responded to conventional treatments like Orthokeratology and atropine eyedrops. The primary focus is to determine if RLRL therapy can limit axial length (AL) elongation to less than 0.1mm per year and spherical equivalent refraction (SER) progression to less than 0.25 diopter per year, while also evaluating safety and visual outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Myopia

Currently open trials in the same condition.

Other The Hong Kong Polytechnic University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06569810.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing